Stress Response and Sleep Changes is the main area connected here, and any felt benefit should be read together with the human evidence base.
Human evidence exists, but it is mostly in patient or disease contexts, so the score is handled conservatively.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Women's health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This is based on lab markers such as blood levels, deficiency correction, or absorption. Read it separately from directly felt outcomes.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Standalone side-effect signals and combination cautions are listed separately.
The group showed a positive signal, but individual contributions are hard to isolate. Not a stack recommendation.
Paper IDs and full lists are private. Only study types and summaries are shown.
This review goes beyond the classical role of vitamin B6 as a cofactor to highlight new structural and regulatory information that further defines how the vitamin is synthesized and controlled in the cell.
The clinical and biochemical features of disorders leading to B6‐responsive seizures and the treatment of these disorders are described in this review.
These randomized trial data from a large cohort of women at high risk of CVD indicate that daily supplementation with folic acid/B6/B12 may reduce the risk of age-related macular degeneration.
The first animal model for PDE is reported, an aldh7a1-null zebrafish displaying deficient lysine metabolism and spontaneous and recurrent seizures in the larval stage (10 days postfertilization), which provides valuable insights into PDE pathophysiology.
Both low and high plasma PLP were associated with a significant suppression of molecular and histological markers of inflammation in the colon and, if confirmed, vitamin B6 supplementation may offer an additional tool for the management of IBD.
The phenotype, stress responses, vitamer levels, and regulation of the vitamin B6 pathway genes in Arabidopsis (Arabidopsis thaliana) plants mutant in PDX3 and SOS4 are determined.